COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

被引：0
|
作者：
Su, W. [1 ]
Rengarajan, B. [2 ]
Profant, D. [2 ]
Mayo, K. [1 ]
Groff, M. [3 ]
Tremblay, G. [3 ]
Ganti, A. K. [4 ]
机构：
[1] Jazz Pharmaceut, Philadelphia, PA USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Cytel Inc, Cambridge, MA USA
[4] VA Nebraska Iowa Hlth Care Syst, Omaha, NE USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE152
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Liu, Gordon
    Xie, Feng
    Sheng, Yanan
    Shi, Luwen
    CLINICAL THERAPEUTICS, 2019, 41 (11) : 2308 - 2320
  • [22] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [23] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [24] Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Zaman, K.
    Sala, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C.
    Kahatt, C.
    Siguero, M.
    Zeaiter, A.
    Arrondeau, J.
    Delord, J. -P.
    Martinez, M.
    Anton, A.
    Trigo, Jose M.
    Wannesson, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S19 - S20
  • [25] Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)
    Kim, Y.
    Goto, K.
    Yoh, K.
    Niho, S.
    Ohmatsu, H.
    Kubota, K.
    Saijo, N.
    Nishiwaki, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.
    Cheng, Ying
    Wu, Chunjiao
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinghua
    Wu, Lin
    Li, Juan
    Zhao, Yanqiu
    Li, Xingya
    Zhao, Jun
    Dong, Xiaorong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [28] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [29] Second-Line Therapy for Non-Small-Cell Lung Cancer
    Arango, Belisario A.
    Castrellon, Aurelio B.
    Santos, Edgardo S.
    Raez, Luis E.
    CLINICAL LUNG CANCER, 2009, 10 (02) : 91 - 98
  • [30] ECONOMIC BURDEN IN ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) RECEIVING SECOND-LINE THERAPY: A SYSTEMATIC LITERATURE REVIEW (SLR)
    Kwon, C.
    Nair, A. A.
    Harricharan, S.
    Zhang, X.
    VALUE IN HEALTH, 2022, 25 (07) : S393 - S393
12345